576 Figure 1-figure supplement 1. Transcriptional inhibition after irradiation and 577 transcriptional restart after DNA repair in U2OS cells. A. U2OS cells were either incubated 578 with EU or not, as indicated, and were irradiated (10 Gy) or not as indicated, followed by 579 detection of the EU by click chemistry of a fluorophore, and immunofluorescence staining of 580 gamma H2AX in the same cells and the DNA was detected by Hoechst staining.

581

Figure 1-figure supplement 2. Confirmation of knockdown of HIRA (A) and H3.3 (B). The
samples were from the same experiments shown in Figure 1.

584

Figure 2-figure supplement 1. The mean intensities of the EU peaks shown in Figure 2D are
indicated. The mean value of each sample was calculated by Flowjo software.

588 Figure 3-figure supplement 1. Nascent transcript levels before and after 30 minutes of IR. 589 The samples from two independent experiments were used for the EU-seq and analyses in Fig. 3 590 and 4. 591 592 Figure 3-figure supplement 2. Screen shot from the UCSC browser of nascent transcripts. 593 A. Nascent transcripts before and after IR over ribosomal DNA (rDNA). B. Nascent histone 594 transcripts before and after IR over histone cluster 1. 595 596 Figure 3-figure supplement 3. Validation of nascent transcript levels of DEGs from EU-597 RNA seq by real-time quantitative RT-PCR. Samples from three independent experiments 598 were used for the analyses. Ct value is presented to show the absolute amounts of EU labeled 599 RNA transcripts from the same number of cells before and after 30 minutes of IR (10 gray). 600 Significant difference after IR compared to before IR are indicated by asterisks, where ** 601 indicates p < 0.01, * indicates p < 0.05 and ns indicates non-significant by students T-test. 602 603 Figure 5-figure supplement 1. CRISPR-Cas9 screen identifies genes promoting 604 transcriptional inhibition after IR. A volcano plot of guide RNA changes between Eu high 605 cells and unsorted cells. Labeled genes are some of those that have P adjust $\leq 10^{-6}$. 606 607 Figure 5-figure supplement 2. Confirmation of knockdown of Nae1. gEV is an empty vector. 608 The samples were from the same experiments shown in Figure 5D. 609

610	Figure 6-figure supplement 1. Analysis of CUL4A and CUL4B depletion. A. The western
611	blot shows the CUL4A and CUL4B levels from the experiment shown in Fig. 6B. Additionally
612	gRNAs were used to deplete CUL4A in cul4b cells and CUL4B in cul4a cells and their western
613	blot analyses are also shown. B. The EU analysis of these double depleted cells is shown. C. Cell
614	cycle analysis of the experiment shown in A and B and Fig. 6B.
615	
616	Figure 6-figure supplement 2. Cell cycle analysis of cells treated with MLN4924 and
617	RO3306 . MLN4924 or RO3306 treatment leads cell cycle arrest in G ₂ phase.
618	
619	Figure 7-figure supplement 1. Quantification of cells with TOPBP1 expression before and
620	after IR (10 Gy) in cells treated with MLN4924 and RO-3306. The samples were from the same
621	experiments shown in Fig. 7F, 7G.
622	
623	Supplementary File 1. Nascent RNA profiles of each gene using EU RNA-seq.
624	
625	Supplementary File 2. Significantly enriched GO terms for up-regulated gene after irradiation.
626	
627	Supplementary File 3. Significantly enriched GO terms for down-regulated genes after
628	irradiation.
629	
630	Supplementary File 4. Whole genome CRISPR-Cas9 screen detects the abundance of all
631	gRNAs and target genes for EU high cells and unsorted cells.
632	

633	Figure 1-figure supplement 2 Source Data 1. Original file for the Western blot analysis in					
634	Figure 1-Figure Supplement 1A (anti-HIRA and anti-GAPDH).					
635						
636	Figure 1-figure supplement 2 Source Data 2. PDF containing Figure 1-Figure Supplement 1A					
637	and original scans of the relevant Western blot analysis (anti-CUL4A, anti-CUL4B and anti-					
638	GAPDH) with highlighted bands and sample labels.					
639						
640	Figure 1-figure supplement 2 Source Data 3. Original file for the Western blot analysis in					
641	Figure 1-Figure Supplement 1B (anti-H3.3 and anti-GAPDH).					
642						
643	Figure 1-figure supplement 2 Source Data 4. PDF containing Figure 1-Figure Supplement 1B					
644	and original scans of the relevant Western blot analysis (anti-H3.3 and anti-GAPDH) with					
645	highlighted bands and sample labels.					
646						
647						
648	Figure 5-figure supplement 2 Source Data 1. Original file for the Western blot analysis in					
649	Figure 5D (anti-Nae1 and anti-GAPDH).					
650						
651	Figure 5-figure supplement 2 Source Data 2. PDF of Western blot analysis in Figure 5D and					
652	original scans of the relevant Western blot analysis (anti-Nae1 and anti-GAPDH) with					
653	highlighted bands and sample labels.					
654						

655	Figure 6 Source Data 1. Original file for the Western blot analysis in Figure 6A (anti-CUL4A,
656	anti-CUL4B and anti-GAPDH).
657	
658	Figure 6 Source Data 2. PDF containing Figure 6A and original scans of the relevant Western
659	blot analysis (anti-CUL4A, anti-CUL4B and anti-GAPDH) with highlighted bands and sample
660	labels.
661	
662	Figure 6 Source Data 3. Original file for the Western blot analysis in Figure 6C (anti-CUL4B,
663	and anti-GAPDH).
664	
665	Figure 6 Source Data 4. PDF containing Figure 6C and original scans of the relevant Western
666	blot analysis (anti-CUL4B and anti-GAPDH) with highlighted bands and sample labels.
667	
668	Figure 6-figure supplement 1 Source Data 1. Original file for the Western blot analysis in
669	Figure 6-figure supplement 1A (anti-CUL4A, anti-CUL4B and anti-GAPDH).
670	
671	Figure 6-figure supplement 1 Source Data 2. PDF containing Figure 6-figure supplement 1A
672	and original scans of the relevant Western blot analysis (anti-CUL4A, anti-CUL4B and anti-
673	GAPDH) with highlighted bands and sample labels.

Figure 1-figure supplement 1



Figure 1-figure supplement 2

Α





Figure 2-figure supplement 1

Dose	No EU	No IR	15 m	30 m	1 h	2 h	4 h
2 Gy	314	2690	1440	1261	1282	1640	2349
5 Gy	314	2690	1379	1169	1101	1345	2004
10 Gy	314	2690	1224	1094	1053	1347	1803

Figure 3-figure supplement 1



Figure 3-figure supplement 2





Figure 5-figure supplement 1



Figure 5-figure supplement 2



Figure 6-figure supplement 1



10²

50K

100К 150К **7-ААД**



200K 250K

Figure 6-figure supplement 2



